Loading…

The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS

EXO-CD24 are exosomes genetically manipulated to over-express Cluster of Differentiation (CD) 24. It consists of two breakthrough technologies: CD24, the drug, as a novel immunomodulator that is smarter than steroids without any side effects, and exosomes as the ideal natural drug carrier. A randomi...

Full description

Saved in:
Bibliographic Details
Published in:Respiratory research 2024-04, Vol.25 (1), p.151-151, Article 151
Main Authors: Grigoropoulos, Ioannis, Tsioulos, Georgios, Kastrissianakis, Artemis, Shapira, Shiran, Green, Orr, Rapti, Vasiliki, Tsakona, Maria, Konstantinos, Thomas, Savva, Athina, Kavatha, Dimitra, Boumpas, Dimitrios, Syrigos, Konstantinos, Xynogalas, Ioannis, Leontis, Konstantinos, Ntousopoulos, Vasileios, Sakka, Vissaria, Sardelis, Zafeiris, Fotiadis, Andreas, Vlassi, Lamprini, Kontogianni, Chrysoula, Levounets, Anastasia, Poulakou, Garyfalia, Gaga, Mina, MacLoughlin, Ronan, Stebbing, Justin, Arber, Nadir, Antoniadou, Anastasia, Tsiodras, Sotirios
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:EXO-CD24 are exosomes genetically manipulated to over-express Cluster of Differentiation (CD) 24. It consists of two breakthrough technologies: CD24, the drug, as a novel immunomodulator that is smarter than steroids without any side effects, and exosomes as the ideal natural drug carrier. A randomized, single blind, dose-finding phase IIb trial in hospitalized patients with mild to moderate Coronavirus disease 2019 (COVID-19) related Acute Respiratory Distress Syndrome (ARDS) was carried out in two medical centers in Athens. Patients received either 10 or 10 exosome particles of EXO-CD24, daily, for five consecutive days and monitored for 28 days. Efficacy was assessed at day 7 among 91 patients who underwent randomization. The outcome was also compared in a post-hoc analysis with an income control group (n = 202) that fit the inclusion and exclusion criteria. The mean age was 49.4 (± 13.2) years and 74.4% were male. By day 7, 83.7% showed improved respiratory signs and 64% had better oxygen saturation (SpO ) (p 
ISSN:1465-993X
1465-9921
1465-993X
1465-9921
DOI:10.1186/s12931-024-02759-5